Reports Q3 revenue $67.5M, consensus $64.53M. “The Company delivered outstanding financial and business results in the third quarter, with strong revenue growth and even higher profitability growth, a significant inflection in operating cash flow, and continued progess across a number of key business initiatives,” said Nick Colangelo, President and CEO of Vericel (VCEL). “We believe that the Company is very well-positioned for a strong close to the year and to continue to deliver a unique combination of sustained high revenue and profit growth in 2026 and beyond based on the strength of our core portfolio, the recent launch of MACI Arthro and the continued progress on our long-term growth initiatives.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- VCEL Upcoming Earnings Report: What to Expect?
- Vericel price target lowered to $41 from $46 at Truist
- Vericel’s Promising Growth: Buy Rating Backed by MACI Revenue Surge and Successful MACI Arthro Launch
- Vericel’s Strategic Growth and Market Expansion Drive Buy Rating
- Vericel downgraded to Neutral from Buy at BTIG